证券代码：603363 证券简称：*ST 傲农 公告编号：2024-115 福建傲农生物科技集团股份有限公司 2024 年 4 月养殖业务主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 福建傲农生物科技集团股份有限公司（以下简称"公司"）现将 2024 年 4 月养殖业务主要经营数据披露如下： 一、2024 年 4 月养殖业务主要经营数据 单位：万头 | 主要产品 | 销售量 | 库存量 | 销售量同比 | 库存量同比 | | --- | --- | --- | --- | --- | | | | | 增减（%） | 增减（%） | | 生猪 | 15.52 | 46.90 | -63.78 | -80.60 | 注：生猪销售量包含公司养殖生猪通过公司食品板块子公司对外销售的数量。 2024 年 4 月，公司生猪销售量 15.52 万头，同比减少 63.78%。 2024 年 4 月末，公司生猪存栏 46.90 万头，较 2023 年 4 月末减少 80.60%， 较 2023 年 12 月末减少 57.26 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东漳州傲农投资有限公司（原名称为"厦门傲农投资有限公 司"，以下简称"傲农投资"）持有本公司股份总数为 266,173,069 股，占公司总 股本的 30.58%。截至 2024 年 5 月 6 日，傲农投资被司法冻结和司法标记的股份 数累计为 266,173,069 股，占其所持股份数的 100%，占本公司总股本的 30.58%。 傲农投资及其一致行动人吴有林先生（公司实际控制人）、漳州芗城百 瑞投资合伙企业（有限合伙）（原名"厦门裕泽投资合伙企业（有限合伙）"以 下简称"百瑞投资"）、吴有材先生、傅心锋先生、张明浪先生、郭庆辉先生合 计持有本公司股份总数为 394,171,600 股，占公司总股本的 45.29%。截至 2024 年 5 月 6 日，傲农投资及其一致行动人合计被司法冻结和司法标记股份数累计为 362,196,261 股，占其合计持股数量的 91.89%，占公司总股本的 41.62%。 综合考虑近期傲农投资、吴有林先生、百瑞投资部分股份 ...

证券代码：603363 证券简称：傲农生物 公告编号：2024-112 福建傲农生物科技集团股份有限公司 关于新增部分债务逾期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次债务逾期情况 福建傲农生物科技集团股份有限公司及子公司（以下简称"公司"）由于 流动资金紧张，导致公司及部分子公司出现部分债务未能如期偿还的情形。截 至 2024 年 4 月 29 日，公司在金融机构新增逾期的债务本息合计约 15,733.73 万元，占公司最近一期经审计净资产的 16.34%。具体情况如下： 1.逾期的银行债务 单位：万元 | 序号 | 债务人 | 债权人 | 逾期金额 （万元） | 到期日 | | --- | --- | --- | --- | --- | | 1 | 傲农佑康科技有限公司 | 租赁机构 | 291.71 | 2024/4/20 | | 2 | 漳浦县赵木兰养殖有限公司 | 租赁机构 | 57.85 | 2024/4/20 | | 3 | 庆云傲农旭成现代农业开发有限公司 | 租赁机构 | 347.12 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 福建傲农生物科技集团股份有限公司（以下简称"公司"或"傲农生物"） 2024 年 4 月 4 日于上海证券交易所网站（www.sse.com.cn）披露了《关于召开 预重整第一次临时债权人会议的公告》（公告编号：2024-087），公司预重整临 时管理人（以下简称"临时管理人"）定于 2024 年 4 月 19 日（星期五）上午 10:30 通过"小火鸟智慧破产平台"通过网络形式召开公司预重整第一次临时债 权人会议（以下简称"本次会议"）。 公司于 2024 年 4 月 20 日于上海证券交易所网站（www.sse.com.cn）披露了 《关于预重整第一次临时债权人会议召开情况的公告》（公告编号：2024-093）， 公司预重整第一次临时债权人会议在"小火鸟智慧破产平台"以网络会议直播方 式按时召开，在 2024 年 4 月 30 日 12:00 前完成表决，逾期未提交表决结果的， 视为赞成该表决事项。 2024 年 4 月 30 日，公司收到临时管理人发来的《福建傲农生物科技集 ...

证券代码：603363 证券简称：傲农生物 公告编号：2024-111 福建傲农生物科技集团股份有限公司 关于新增涉及诉讼、仲裁事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 案件所处的诉讼（仲裁）阶段：公司 2024 年 4 月 24 日至今新增诉讼（仲 裁）金额 27,837.14 万元，其中尚未结案诉讼、仲裁案件金额为 27,837.14 万元， 已结案诉讼、仲裁案件金额为 0.00 万元。 上市公司所处的当事人地位：原告、被告；申请人、被申请人等。 涉案的金额：公司 2024 年 4 月 24 日至今新增诉讼（仲裁）金额 27,837.14 万元，2022 年 11 月至今累计诉讼（仲裁）金额 437,563.82 万元。 是否会对上市公司损益产生负面影响：鉴于部分诉讼、仲裁案件尚未开 庭审理或尚未结案，上述事项对公司本期利润或期后利润的影响存在不确定性。 敬请投资者理性投资，注意投资风险。 根据《上海证券交易所股票上市规则》有关规定，福建傲农生物科技集团股 份有限公司对公司及下属控股子公司 ...

Financial Performance - The company reported a net profit attributable to shareholders of -3,650,822,227.67 RMB for 2023, marking a continuous loss for three consecutive years[6]. - The cumulative undistributed profit at the end of the reporting period stands at -1,449,244,380.68 RMB, indicating a need for cautious cash flow management[6]. - The company plans not to distribute profits or conduct cash dividends for the 2023 fiscal year due to the cyclical impact of the pig farming industry and low pig prices[6]. - The company's operating revenue for 2023 was CNY 19,457,641,131.79, representing a decrease of 9.97% compared to the previous year[23]. - The net profit attributable to shareholders of the listed company was CNY -3,650,822,227.67, which is a significant decline from CNY -1,038,366,505.16 in 2022[23]. - The total assets decreased by 27.00% to CNY 13,625,213,490.65 at the end of 2023 compared to the end of 2022[23]. - The basic earnings per share for 2023 was CNY -4.21, a decline from CNY -1.34 in 2022[24]. - The weighted average return on equity was -660.02%, a decrease of 610.30 percentage points from the previous year[24]. - The company reported a net loss of CNY -2,360,934,286.92 in the fourth quarter of 2023[26]. - The company's total revenue for 2023 was CNY 1,945,764.11 million, a decrease of 9.97% compared to the previous year[73]. - The net profit attributable to shareholders was a loss of CNY 365,082.22 million, an increase in loss of CNY 261,245.57 million compared to the previous year[73]. Operational Challenges - The company emphasizes the importance of maintaining a stable operation and improving its asset-liability structure in light of recent financial challenges[6]. - The audit report from Rongcheng Accounting Firm highlighted significant uncertainties regarding the company's ability to continue as a going concern[5]. - The company has faced risks related to its future development, which are discussed in detail in the management's analysis section[9]. - The average price of live pigs decreased by 14.0% year-on-year, leading to significant operational challenges for the company[33]. - The feed industry faced high raw material prices throughout the year, impacting cost control for feed and downstream breeding enterprises[33]. - The company experienced significant operational losses due to a prolonged downturn in pig prices and reduced sales scale in feed and trade[67]. - The company recognizes the risks of animal diseases, raw material price fluctuations, and high asset-liability ratios, which could impact its operations[127][128]. Business Strategy and Development - The company plans to enhance its pig breeding sector's efficiency and innovation capabilities to improve product quality and market competitiveness[34]. - The company is focusing on cost reduction and efficiency improvement across all business segments to enhance operational management[36]. - The company aims to establish a stable supply chain and develop differentiated pork products to increase consumer loyalty and brand strength[35]. - The company is focusing on modernizing the livestock industry and promoting the transformation towards large-scale, standardized, and eco-friendly production methods[49]. - The company aims to strengthen its competitive position in the feed market through continuous technological innovation and product upgrades[63]. - The company is committed to maintaining positive cash flow and profitability in its feed and food segments while reducing losses in pig farming[124]. - The company plans to optimize its core industry chain of feed, pig farming, and food, focusing on resource integration and improving operational efficiency[124]. Research and Development - The company has a total of 453 patents, including 128 invention patents, indicating strong research and development capabilities[71]. - The company is developing key technologies for antibiotic-free feed additives, currently in the trial production stage[91]. - The company is upgrading piglet feed to enhance immunity and improve gut health, with several products in the trial production stage[92]. - The company is focusing on the development of high-efficiency breeding technologies and specialized breeding systems for various livestock[91]. - The company is conducting research on the impact of various feed additives and nutritional strategies to enhance animal health and performance[94]. - Research and development investments increased by 30%, focusing on innovative feed solutions and sustainable practices[152]. Corporate Governance and Management - The company has established an independent financial management system, ensuring that it operates without interference from its controlling shareholder[137]. - The company actively engages with investors through various channels, enhancing transparency and communication[136]. - The company has implemented strict measures to manage credit risks associated with customer financing, ensuring that funds are used specifically for purchasing products or project construction[131]. - The company has a structured process for determining the remuneration of its directors and senior management, ensuring alignment with company performance[159]. - The company is committed to maintaining transparency and governance standards as it navigates through leadership changes[148]. - The company has seen a turnover in its board, with key positions being vacated and new appointments being made[160]. Environmental Responsibility - The company has invested approximately 22.60 million in environmental protection during the reporting period[194]. - The wastewater treatment facilities have been reported to operate stably during the reporting period, meeting all discharge standards[199]. - The company has enhanced green spaces around pig farms to improve air quality through strategic planting[200]. - The company has established a systematic approach for the disposal of medical waste and dead livestock, ensuring compliance with environmental regulations[200]. - The company utilizes anaerobic and aerobic treatment methods, with treated wastewater being stored for further biological processing and irrigation purposes[200]. Future Outlook - The company aims to become a world-class agricultural and food enterprise by 2030, focusing on the integration of agriculture and food sectors[120]. - The company aims for a feed sales target of 2.5 million tons and a pig output of 1.5 to 2 million heads in 2024, with a food revenue target of 2.5 billion yuan[124]. - Overall, the company remains optimistic about future growth, driven by strategic initiatives and market expansion efforts[152].

证券代码：603363 证券简称：傲农生物 公告编号：2024-109 关于召开 2023 年度暨 2024 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 05 月 20 日（星期一）上午 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 05 月 13 日（星期一）至 05 月 17 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 anzq@aonong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 福建傲农生物科技集团股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司《2023 年年度报告》 及《2024 年第一季度报告》，为便于广大投资者更全面深入地了解公 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 2,407,845,116.90, representing a decrease of 50.02% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 292,019,915.86, with a significant impact from low pig prices and idle breeding facilities[5][8]. - The diluted earnings per share for the period was -CNY 0.34, reflecting a substantial decline in profitability[6][8]. - The company reported a significant reduction in pig sales and feed sales, contributing to the overall decline in revenue[8]. - The net profit attributable to shareholders was a loss of CNY 29,201.99 million in the same period[12]. - The primary reason for the loss was the low prices of live pigs and the optimization of inefficient breeding units, leading to closures and associated costs[12]. - The company reported a net loss of CNY 5,915,893,879.65 in Q1 2024, worsening from a loss of CNY 5,623,873,963.79 in Q1 2023[20]. - The company's net profit for Q1 2024 was -372,743,346.37 CNY, compared to -250,464,569.13 CNY in Q1 2023, representing a decline of approximately 48.8%[24]. - The company reported a total comprehensive loss of -372,779,069.90 CNY in Q1 2024, compared to -250,821,928.97 CNY in Q1 2023, reflecting an increase in losses of about 48.6%[25]. - The basic earnings per share for Q1 2024 was -0.34 CNY, compared to -0.21 CNY in Q1 2023, indicating a worsening performance[25]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 28,696,382.95, down 111.36% year-on-year, primarily due to decreased sales in feed and food segments[5][8]. - Operating cash flow for Q1 2024 was -28,696,382.95 CNY, a significant decrease from 252,705,770.68 CNY in Q1 2023[27]. - Cash and cash equivalents at the end of Q1 2024 were 144,182,514.25 CNY, down from 396,770,516.87 CNY at the end of Q1 2023, a decrease of approximately 63.7%[28]. - The total cash outflow from operating activities in Q1 2024 was 2,353,957,896.84 CNY, compared to 4,655,057,232.12 CNY in Q1 2023, showing a reduction of about 49.6%[27]. - Investment activities generated a net cash inflow of 60,620,390.18 CNY in Q1 2024, contrasting with a net cash outflow of -190,643,786.85 CNY in Q1 2023[28]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,599,649,513.69, a decrease of 7.53% from the end of the previous year[6]. - Total liabilities amounted to CNY 13,461,999,084.53 in Q1 2024, down from CNY 14,128,429,997.37 in Q1 2023, representing a decrease of 4.71%[19]. - The company's total equity showed a decline, with a total of CNY -862,349,570.84 in Q1 2024 compared to CNY -503,216,506.72 in Q1 2023[20]. - Inventory decreased to CNY 992,625,221.01 in Q1 2024 from CNY 1,328,135,336.11 in Q1 2023, a reduction of 25.29%[18]. - Long-term equity investments fell to CNY 141,599,694.91 in Q1 2024 from CNY 249,153,592.85 in Q1 2023, a decrease of 43.12%[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 96,571[10]. - The largest shareholder, Zhangzhou Aonong Investment Co., Ltd., held 30.58% of the shares, with a total of 266,173,069 shares[10]. Business Strategy and Restructuring - The company is undergoing a pre-restructuring process initiated in February 2024 due to three years of losses and liquidity issues[16]. - The restructuring aims to enhance liquidity, improve asset quality, and focus on business restructuring to recover operational performance[16]. - The company plans to integrate resources around a "feed as the main body, breeding and food as two wings" strategy[13]. - The company aims to optimize its core business chain of feed, pig farming, and food to enhance market competitiveness[15]. - The cyclical nature of the pig farming industry significantly impacts the company's overall performance, with market price fluctuations posing risks[15]. Revenue and Cost Analysis - Total revenue for Q1 2024 was CNY 2,407,845,116.90, a decrease of 50.05% compared to CNY 4,817,861,444.34 in Q1 2023[23]. - Total operating costs for Q1 2024 were CNY 2,857,161,795.48, down 44.41% from CNY 5,132,874,635.39 in Q1 2023[23]. - Total revenue from sales and services in Q1 2024 was 2,238,551,004.30 CNY, down from 4,812,041,400.28 CNY in Q1 2023, indicating a decline of about 53.5%[26]. - The feed business maintained a gross margin of 5.43%, an increase of 0.04 percentage points compared to Q1 2023[12]. - Research and development expenses decreased to 14,555,686.01 CNY in Q1 2024 from 47,317,920.67 CNY in Q1 2023, a reduction of approximately 69.1%[24]. - The company incurred financial expenses of 110,030,995.61 CNY in Q1 2024, slightly down from 123,474,106.79 CNY in Q1 2023[24].

证券代码：603363 证券简称：傲农生物 公告编号：2024-097 截至 2024 年 3 月 31 日，公司及下属子公司为产业链合作伙伴提供的担保余 额前五名的情况如下： 一、担保情况概述 福建傲农生物科技集团股份有限公司（以下简称"公司"或"本公司"）于 2024 年 2 月 4 日召开的第四届董事会第四次会议审议通过了《关于 2024 年度为 产业链合作伙伴提供担保的议案》、《关于 2024 年度公司及下属子公司相互提 供担保的议案》，内容包括： 1、同意公司及下属子公司 2024 年度为公司及下属子公司的下游客户、产业 链供应商、公司养殖放养业务的合作养户等产业链合作伙伴提供不超过 12 亿元 的担保。 2、同意公司及下属全资、控股子公司在 2024 年度继续相互提供担保，其中 公司为下属资产负债率低于 70%的子公司提供最高担保金额 28 亿元；公司为下 属资产负债率 70%以上的子公司提供最高担保金额 66 亿元；公司下属全资、控 股子公司为公司其他下属资产负债率低于 70%的子公司提供最高担保金额 6 亿 元；公司下属全资、控股子公司为公司其他下属资产负债率 70%以上的子公司提 供最高担保 ...

证券代码：603363 证券简称：傲农生物 公告编号：2024-096 福建傲农生物科技集团股份有限公司 关于新增涉及诉讼、仲裁事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 案件所处的诉讼（仲裁）阶段：公司 2024 年 3 月 30 日至今新增诉讼（仲 裁）金额 52,903.26 万元，其中尚未结案诉讼、仲裁案件金额为 52,046.96 万元， 已结案诉讼、仲裁案件金额为 856.30 万元。 上市公司所处的当事人地位：原告、被告；申请人、被申请人等。 涉案的金额：公司 2024 年 3 月 30 日至今新增诉讼（仲裁）金额 52,903.26 万元，2022 年 11 月至今累计诉讼（仲裁）金额 409,726.68 万元。 是否会对上市公司损益产生负面影响：鉴于部分诉讼、仲裁案件尚未开 庭审理或尚未结案，上述事项对公司本期利润或期后利润的影响存在不确定性。 敬请投资者理性投资，注意投资风险。 根据《上海证券交易所股票上市规则》有关规定，福建傲农生物科技集团股 份有限公司对公司及下属控股子 ...